AbbVie Inc (ABBV)

$134.21 -$8.51 (-5.96%)

Sign Up to Unlock Features

Subscribe

AbbVie Inc (ABBV)

$134.21 -$8.51 (-5.96%)

Data as of last close (September 30, 2022)
Dividend

Ranking

Safety

Ranking

Value

Ranking

Momentum

Ranking

The Strike Zone
Strike Zone Factors
Option Snapshot
Next Dividend / EPS Dates
Next Ex Div Date (Est.) Next EPS Date (Est.)
N/A N/A
Stock Chart
Stock Summary
Last price (Close) $134.21
52-Week High (4/8/22) $175.91
52-Week Lo (10/19/21) $106.86
% Below 52-Week High -23.71%
Relative Strength Index (RSI) (14-day) 37.4
Market Cap. ($ Bil) $237.30
Avg. Daily Volume (30D) 5,466,123
Beta (5Y,all) 0.68
Historical Volatility (5Y,all) (%) 28.2%
Maximum Drawdown (5Y,all) (%) 45.1%
Pullback as % of Max. DD 52.6%
Sector/Industry
Healthcare
Drug Manufacturers - General
Business Description

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was…

www.abbvieinvestor.com Read more
Dividend Summary
Dividend Yield (%) 4.20%
Annual Payout (Fwd.) $5.64
Next Ex-Div Amount (Est.) $1.41
Dividend Growth (Yrs.)
Dividend Growth (1-year) (%)
Dividend CAGR (5-year) (%)
Dividend CAGR (10-year) (%)
Payout Ratio (Fwd.) (%) 40.7%
Payment Frequency Quarterly
Payment Months 1, 4, 7, 10
Total Return / Momentum
Period Return vs. Ind. vs. S&P
1 Week -6.19% -7.04% -3.27%
1 Month -0.99% 0.30% 9.06%
3 Months -12.37% 0.60% -7.10%
1 Year 24.42% 29.21% 41.18%
5 Years 51.04% 2.16% 8.71%
Valuation Summary
Multiple Current Forward 5yr Avg.
P/Sales 4.16x 4.30x 4.26x
P/E 19.01x 11.28x 25.20x
P/Book 16.19x N/A N/A
EV/EBITDA 12.23x 9.52x 16.31x
Share. Yield % 4.88%
Annual Sales & EPS
LFQ Sales (12/31/2021) $56,197
LFQ EPS (12/31/2021) $6.45
Fwd Sales Est. (12/31/2022) $59,006
Fwd EPS Est. (12/31/2022) $13.86
Quarterly Sales & EPS
LFQ Sales (6/2022) $14,583
LFQ EPS (6/2022) $0.51
Fwd Sales Est. (9/2022) $15,848
Fwd EPS Est. (9/2022) $3.75
Yahoo Finance News
  • Starter Stock Portfolio: 15 Safe Stocks To Buy March 30, 2023
    In this article, we will take a look at the 15 safe stocks to buy. To see more such companies, go directly to Starter Stock Portfolio: 5 Safe Stocks To Buy. Amid the current market turmoil which seems to have no end in sight, it feels weird to label anything as “safe,” especially stocks, which […]
  • 2 High-Yielding Dividend Investments to Buy for the Long Haul March 30, 2023
    Both of these stocks are Dividend Kings, and their payouts are likely to continue rising in the future.
  • 12 Most Promising Healthcare Stocks According to Analysts March 29, 2023
    In this article, we will take a look at the 12 most promising healthcare stocks according to analysts. To see more such companies, go directly to 5 Most Promising Healthcare Stocks According to Analysts. 2023 is turning out to be a horrific year for financial markets as investors are starting to see a glimpse of […]
  • Better Growth Stock: Vertex Pharmaceuticals vs. AbbVie March 29, 2023
    Vertex Pharmaceuticals (NASDAQ: VRTX) and AbbVie (NYSE: ABBV) both beat last year's bear market. Vertex and AbbVie also happen to offer a lot of growth potential. Vertex has a new potential blockbuster drug on the horizon.
  • Allergan Aesthetics* to showcase 360° approach to clinical practice, aesthetic products, and patients with expert-led symposia at AMWC 2023 March 29, 2023
    Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, will be showcasing its customer-centric 'Discover Your 360°' approach to aesthetics at the 21st Anti-Aging and Aesthetics Medicine World Congress (AMWC) in Monaco from 30 March - 1 April 2023, supporting practitioners to help patients 'unlock their individuality' in an evolving world. Events include two Allergan Medical Institute […]
  • Better Growth Stock: AbbVie vs. Pfizer March 29, 2023
    AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) are two of the world's biggest pharmaceutical companies, and the similarities don't end there. The case for AbbVie as a growth stock can't avoid two issues: the decline of Humira, and the stagnation of its oncology portfolio.
  • AbbVie Walks Away From CytomX Partnership, But Garnering Attention Of Big Pharma Partners March 28, 2023
    CytomX Therapeutics Inc (NASDAQ: CTMX) will weigh its options for CX-2029, a CD71-directed antibody-drug conjugate, after AbbVie Inc (NYSE: ABBV) decided not to advance the drug into additional studies. CytomX and AbbVie have also concluded their research activities under a 2016 Discovery License and Collaboration Agreement. AbbVie paid $30 million upfront in 2016 to ink […]
  • 2 Relatively Safe Dividend Stocks You Won't Regret Owning March 28, 2023
    While there's no ironclad method for picking perfectly safe stocks, thankfully there are a few dividend-paying companies that are a bit less risky than average -- as a result of their history of effective competition and their management's skill at executing their business models. Both of the stocks I'll review in a moment are likely […]
  • This Is the Best Dividend ETF You Can Buy March 28, 2023
    The Schwab U.S. Dividend ETF (NYSEMKT: SCHD) just went through its annual reconstitution, meaning the top positions look different than they did just a few weeks prior. AbbVie (NYSE: ABBV) is now the fund's largest weighted position.
  • CIBC introduces additional Canadian Depositary Receipts ("CDRs") March 28, 2023
    CIBC today announced the addition of six new Canadian Depositary Receipts ("CDRs"), now listed on the NEO Exchange.
Stock Twits
>